Cooper Financial Group’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $352K | Buy |
14,633
+1,883
| +15% | +$49.3K | 0.03% | 313 |
|
|
2026
Q1 | $358K | Buy |
12,750
+1,757
| +16% | +$46.8K | 0.04% | 297 |
|
|
2025
Q4 | $274K | Sell |
10,993
-343
| -3% | -$8.65K | 0.03% | 317 |
|
|
2025
Q3 | $289K | Sell |
11,336
-2,069
| -15% | -$51.1K | 0.03% | 304 |
|
|
2025
Q2 | $325K | Sell |
13,405
-4,909
| -27% | -$114K | 0.04% | 285 |
|
|
2025
Q1 | $464K | Buy |
18,314
+1,716
| +10% | +$44.9K | 0.06% | 246 |
|
|
2024
Q4 | $440K | Sell |
16,598
-2,094
| -11% | -$56.8K | 0.05% | 260 |
|
|
2024
Q3 | $541K | Sell |
18,692
-225
| -1% | -$6.56K | 0.07% | 234 |
|
|
2024
Q2 | $529K | Buy |
18,917
+9,831
| +108% | +$271K | 0.08% | 213 |
|
|
2024
Q1 | $252K | Sell |
9,086
-186
| -2% | -$5.16K | 0.04% | 311 |
|
|
2023
Q4 | $267K | Buy |
9,272
+58
| +0.6% | +$1.75K | 0.05% | 288 |
|
|
2023
Q3 | $306K | Sell |
9,214
-9,017
| -49% | -$319K | 0.07% | 257 |
|
|
2023
Q2 | $669K | Sell |
18,231
-6,702
| -27% | -$261K | 0.17% | 150 |
|
|
2023
Q1 | $1.02M | Buy |
24,933
+5,957
| +31% | +$257K | 0.27% | 93 |
|
|
2022
Q4 | $972K | Buy |
18,976
+633
| +3% | +$30.3K | 0.3% | 84 |
|
|
2022
Q3 | $803K | Buy |
18,343
+647
| +4% | +$31.4K | 0.29% | 88 |
|
|
2022
Q2 | $928K | Buy |
17,696
+1,938
| +12% | +$98.8K | 0.34% | 79 |
|
|
2022
Q1 | $816K | Buy |
15,758
+5,959
| +61% | +$309K | 0.31% | 70 |
|
|
2021
Q4 | $579K | Sell |
9,799
-3,420
| -26% | -$169K | 0.22% | 106 |
|
|
2021
Q3 | $569K | Buy |
13,219
+160
| +1% | +$7.09K | 0.12% | 118 |
|
|
2021
Q2 | $511K | Sell |
13,059
-55
| -0.4% | -$2.14K | 0.1% | 120 |
|
|
2021
Q1 | $475K | Sell |
13,114
-4,571
| -26% | -$162K | 0.11% | 128 |
|
|
2020
Q4 | $651K | Buy |
17,685
+5,212
| +42% | +$191K | 0.13% | 128 |
|
|
2020
Q3 | $434K | Buy |
12,473
+486
| +4% | +$17K | 0.13% | 117 |
|
|
2020
Q2 | $372K | Buy |
11,987
+2,769
| +30% | +$94.1K | 0.12% | 117 |
|
|
2020
Q1 | $285K | Buy |
9,218
+3,176
| +53% | +$108K | 0.12% | 110 |
|
|
2019
Q4 | $225K | Sell |
6,042
-818
| -12% | -$29.1K | 0.09% | 141 |
|
|
2019
Q3 | $234K | Sell |
6,860
-5,853
| -46% | -$213K | 0.11% | 123 |
|
|
2019
Q2 | $523K | Buy |
12,713
+1,145
| +10% | +$45.5K | 0.25% | 62 |
|
|
2019
Q1 | $466K | Sell |
11,568
-1,058
| -8% | -$42.4K | 0.26% | 58 |
|
|
2018
Q4 | $523K | Buy |
+12,626
| New | +$524K | 0.35% | 44 |
|
Other funds holding PFE
Cooper Financial Group's PFE Position: Q2 2026 in Review
Cooper Financial Group increased its Pfizer (PFE) stake by 15% in Q2 2026, buying an estimated $49.3K and bringing the position to 14,633 shares worth $352K. The position accounts for 0.03% of the portfolio, ranked #313.
Cooper Financial Group first reported a position in PFE in Q4 2018 and has held it in 31 quarters since. The position peaked at $1.02M in Q1 2023. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Cooper Financial Group held 14,633 shares of Pfizer worth $352K as of Q2 2026.
- Cooper Financial Group bought 1,883 Pfizer shares in Q2 2026, an estimated $49.3K.
- Pfizer made up 0.03% of Cooper Financial Group's portfolio in Q2 2026, its #313 holding.
- Cooper Financial Group first reported a position in Pfizer in Q4 2018 and has held it in 31 quarters since.
- Cooper Financial Group's Pfizer position peaked at $1.02M in Q1 2023.
- 2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Cooper Financial Group's 13F filing for Q2 2026, filed 8 Jul 2026.